patient with right lower colic stoma having increased stoma output mor

patient with right lower colic stoma having increased stoma output more liquid , recently started on fluoxetine , can it be connected ?

Reading File

Finding Sources

Reading File

I now have comprehensive information from multiple authoritative sources to give a thorough answer.

Yes — Fluoxetine Can Directly Cause Increased/Liquid Stoma Output

This is a well-established and clinically significant connection. Here's the breakdown:

Mechanism

The key is serotonin's role in gut physiology. Approximately 95% of the body's serotonin resides in the GI tract, where it regulates intestinal motility, secretion, and sensation. Fluoxetine (an SSRI) blocks serotonin reuptake at the gut level just as it does in the CNS, increasing serotonergic signaling throughout the GI tract.

The GI side effects of SSRIs are mediated primarily through the 5-HT3 receptor, which, when activated, promotes:

Increased intestinal secretion
Accelerated intestinal transit
Reduced absorption time → looser, higher-volume output

"Most of the body's serotonin is in the GI tract, and serotonergic drugs often cause varying degrees of stomach pain, nausea, flatulence, and diarrhea." — Kaplan and Sadock's Synopsis of Psychiatry

"GI side effects are widespread and are mediated mainly through effects on the serotonin 5-HT3 receptor. The most frequent GI complaints are nausea, diarrhea, anorexia, vomiting, flatulence, and dyspepsia." — Kaplan and Sadock's Synopsis of Psychiatry

Why It's More Noticeable in a Colostomy Patient

A patient with a right lower colic (ascending/transverse) stoma already has inherently higher-output, more liquid effluent than a sigmoid colostomy, because less colon is available for water reabsorption. Any drug that accelerates transit or increases secretion will have a magnified effect — liquid output increases further, and there is less colonic "buffering" to compensate.

Time Course

Importantly:

Nausea and loose stools are usually dose-related and transient, often resolving within a few weeks as tolerance develops.
However, flatulence and diarrhea can persist — especially in susceptible individuals.
If symptoms have not settled within 2–4 weeks of starting fluoxetine, this is less likely to be transient adaptation.

"Nausea and loose stools are usually dose-related and transient, usually resolving within a few weeks." — Kaplan and Sadock's Synopsis of Psychiatry

Fluoxetine Is Specifically Listed as a Diarrhea-Causing Drug

Fluoxetine is explicitly listed under CNS medications known to cause diarrhea alongside lithium and levodopa:

"Central nervous system: Alprazolam, meprobamate, levodopa, anticholinergic drugs, fluoxetine, lithium, tacrine" — Yamada's Textbook of Gastroenterology (Box 35.7 — Medications known to cause diarrhea)

Clinical Management Options

Approach	Detail
Reassure and wait	If recently started, GI effects may resolve within 2–4 weeks
Dose reduction	GI effects are dose-related — lowering dose may help
Switch timing	Giving with food can reduce GI effects
Delayed-release formulation	Less GI impact in the first week of treatment
Consider switching	Paroxetine causes more constipation (anticholinergic effect) and may paradoxically be better tolerated in this patient; mirtazapine also has less diarrhea-inducing effect
Avoid abrupt cessation	If switching, taper — especially important with paroxetine to avoid discontinuation syndrome

Bottom Line

Yes, the connection is very likely. Fluoxetine causes diarrhea via 5-HT3-mediated gut hypermotility and increased secretion. In a patient with a right-sided colostomy (already liquid-predominant output), this effect is amplified. The temporal relationship (starting fluoxetine → increased liquid output) strongly supports drug causality. This is a recognized, listed adverse effect in gastroenterology literature.

If the increased output is causing dehydration, electrolyte imbalance, or skin excoriation, switching to an SSRI/antidepressant with a lower diarrhea profile (or adding loperamide short-term while awaiting adaptation) would be warranted.

patient started fluoxetine one month ago , symptoms started 3 weeks ago , she now also feels dizzy on standing up , no other symptoms suggestive of infection

Finding Sources

Reading File

This gives a very clear clinical picture. Here is the complete synthesis:

Clinical Picture: Dehydration-Driven Orthostatic Hypotension

The dizziness on standing is almost certainly orthostatic (postural) hypotension secondary to volume depletion from ongoing high stoma output — not a direct effect of fluoxetine itself.

Connecting the Dots

Timeline	Event
1 month ago	Started fluoxetine
~1 week in	SSRI-induced GI effect → increased liquid stoma output begins
3 weeks ago	Symptoms established
Now	3 weeks of high-output stoma → cumulative fluid and electrolyte loss → intravascular volume depletion → orthostatic hypotension → dizziness on standing

Why SSRIs Don't Cause Orthostatic Hypotension Directly

This is an important distinction:

"Although SSRIs do not cause orthostatic hypotension, they have been implicated in an increased prevalence of falls in older adult nursing home residents." — Kaplan & Sadock's Comprehensive Textbook of Psychiatry

Unlike TCAs (which cause orthostatic hypotension via alpha-adrenergic blockade), SSRIs/fluoxetine do not directly lower blood pressure on standing. So the dizziness is not a direct pharmacological effect of fluoxetine on vascular tone — it is consequential: diarrhea → dehydration → reduced circulating volume → postural drop in BP.

Dehydration from diarrhea is a recognised direct cause of orthostatic hypotension:

"Situational Hypotension: Dehydration (diarrhea, fasting) → Orthostatic hypotension" — Kaplan and Sadock's Synopsis of Psychiatry

What to Assess Now

Clinically urgent:

Postural BP and pulse — confirm orthostatic hypotension (drop ≥20 mmHg systolic or ≥10 mmHg diastolic on standing, or pulse rise ≥30 bpm)
Stoma output volume — high-output stoma is typically defined as >1000–1500 mL/24 hrs
Electrolytes, urea/creatinine — expect: ↑ urea, ↑ creatinine (pre-renal), ↓ Na⁺, ↓ K⁺, ↓ Mg²⁺, metabolic acidosis (from bicarbonate-rich small bowel fluid)
Urine output and skin turgor — assess dehydration severity

Management Priorities

1. Fluid and electrolyte replacement

Oral rehydration if tolerated — sodium-containing fluids (avoid plain water, which worsens hyponatraemia)
IV fluid replacement if moderate-severe dehydration (0.9% NaCl ± K⁺ supplementation)
Check and replace magnesium — commonly depleted in high-output stomas and often missed

2. Reduce stoma output

Loperamide — first-line antidiarrhoeal for high-output stoma; slows gut transit (give before meals)
Codeine phosphate — second-line if loperamide insufficient
Dietary advice: avoid hyperosmolar fluids (fruit juice, sugary drinks), eat small frequent meals

3. Re-evaluate fluoxetine

GI effects should have settled by now (3 weeks in, started at ~1 week) — if they haven't, the GI effect is unlikely to be transient adaptation
Consider switching to an antidepressant with less/no diarrhoeic tendency:
- Mirtazapine — 5-HT3 antagonist, actually reduces nausea/diarrhoea, good option here
- Paroxetine — anticholinergic activity tends toward constipation, but watch for drug interactions
- Discuss with psychiatry/prescriber before changing

4. Do not abruptly stop fluoxetine — though fluoxetine has a long half-life and discontinuation syndrome is less severe than with paroxetine, it should still be tapered

Bottom Line

The dizziness on standing is a red flag for significant dehydration from 3 weeks of fluoxetine-driven high stoma output. This patient needs electrolytes and renal function checked urgently, oral or IV rehydration, and loperamide to reduce output. The persistence of GI symptoms beyond the usual 2-week adaptation window strongly supports reconsidering fluoxetine as the ongoing driver — a switch to mirtazapine would address both the depression and potentially improve gut symptoms.

This is a shared conversation. Sign in to Orris to start your own chat.